{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T14:32:01Z","timestamp":1768919521907,"version":"3.49.0"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,4,12]],"date-time":"2018-04-12T00:00:00Z","timestamp":1523491200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"highfield:communication, Oxford, UK"},{"name":"Fusion MD, Montreal, Canada"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pulmonary Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.pupt.2018.03.005","type":"journal-article","created":{"date-parts":[[2018,4,3]],"date-time":"2018-04-03T10:27:37Z","timestamp":1522751257000},"page":"72-79","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":54,"special_numbering":"C","title":["Ciprofloxacin Dry Powder for Inhalation (ciprofloxacin DPI): Technical design and features of an efficient drug\u2013device combination"],"prefix":"10.1016","volume":"50","author":[{"given":"Pamela J.","family":"McShane","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8473-1625","authenticated-orcid":false,"given":"Jeffry G.","family":"Weers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas E.","family":"Tarara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfred","family":"Haynes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Preeti","family":"Durbha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danforth P.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tobias","family":"Mundry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth","family":"Operschall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2323-442X","authenticated-orcid":false,"given":"J. Stuart","family":"Elborn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pupt.2018.03.005_bib1","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/01.cpm.0000171422.98696.ed","article-title":"Prevalence and economic burden of bronchiectasis","volume":"12","author":"Weycker","year":"2005","journal-title":"Clin. Pulm. Med."},{"key":"10.1016\/j.pupt.2018.03.005_bib2","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1164\/rccm.201203-0487OC","article-title":"Short- and long-term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis","volume":"186","author":"Chalmers","year":"2012","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.pupt.2018.03.005_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.addr.2014.10.009","article-title":"Clinical applications of pulmonary delivery of antibiotics","volume":"85","author":"Flume","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.pupt.2018.03.005_bib4","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1164\/rccm.201210-1937OC","article-title":"Lung microbiota and bacterial abundance in patients with bronchiectasis when clinically stable and during exacerbation","volume":"187","author":"Tunney","year":"2013","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.pupt.2018.03.005_bib5","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1164\/ajrccm.162.2.9910086","article-title":"Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis","volume":"162","author":"Barker","year":"2000","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.pupt.2018.03.005_bib6","unstructured":"Ciprofloxacin summary of product characteristics. https:\/\/www.medicines.org.uk\/emc\/medicine\/20346\/SPC\/Ciproxin+Tablets+500mg\/#PHARMACODYNAMIC_PROPS (Accessed 6 December 2017)."},{"key":"10.1016\/j.pupt.2018.03.005_bib7","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1183\/09031936.00071312","article-title":"Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study","volume":"41","author":"Wilson","year":"2013","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.pupt.2018.03.005_bib8","series-title":"Respiratory Drug Delivery Europe 2011","first-page":"55","article-title":"Device engineering insights into TOBI Podhaler: a development case study of high efficiency powder delivery to cystic fibrosis patients","author":"Maltz","year":"2011"},{"key":"10.1016\/j.pupt.2018.03.005_bib9","unstructured":"R. Endermann, H. Labischinski, C. Ladel, U. Petersen, B. Newton, Treatment of bacterial diseases of the respiratory organs, Patent application US 2004\/0254194 A1, 2004."},{"key":"10.1016\/j.pupt.2018.03.005_bib10","unstructured":"J.P. Wong, Liposome-encapsulated ciprofloxacin, Patent EP0652008 A1, https:\/\/register.epo.org\/application?number=EP94305331 (Accessed 6 December 2017)."},{"key":"10.1016\/j.pupt.2018.03.005_bib11","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.4155\/tde.13.71","article-title":"Liposomal formulations for inhalation","volume":"4","author":"Cipolla","year":"2013","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.pupt.2018.03.005_bib12","doi-asserted-by":"crossref","first-page":"277","DOI":"10.4155\/tde.14.3","article-title":"The PulmoSphere\u2122 platform for pulmonary drug delivery","volume":"5","author":"Weers","year":"2014","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.pupt.2018.03.005_bib13","series-title":"Respiratory Drug Delivery X","first-page":"297","article-title":"Embedded crystals in low density particles: formulation, manufacture, and properties","author":"Weers","year":"2006"},{"key":"10.1016\/j.pupt.2018.03.005_bib14","series-title":"Comparative Biology of the Normal Lung","first-page":"511","article-title":"Phospholipid composition, biosynthesis, and secretion","author":"Rooney","year":"1992"},{"key":"10.1016\/j.pupt.2018.03.005_bib15","first-page":"233","article-title":"Surfactant metabolism","volume":"17","author":"Ikegami","year":"1993","journal-title":"Semin. Perinatol."},{"key":"10.1016\/j.pupt.2018.03.005_bib16","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1089\/jamp.2010.0855","article-title":"Development of an inhaled dry-powder formulation of tobramycin using PulmoSphereTM technology","volume":"24","author":"Geller","year":"2011","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"key":"10.1016\/j.pupt.2018.03.005_bib17","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1021\/acs.molpharmaceut.5b00147","article-title":"Physical characterization of tobramycin inhalation powder I: rational design of a stable engineered-particle formulation for delivery to the lungs","volume":"12","author":"Miller","year":"2015","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.pupt.2018.03.005_bib18","series-title":"Physiochemical Principles of Pharmacy","author":"Florence","year":"2011"},{"key":"10.1016\/j.pupt.2018.03.005_bib19","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1023\/A:1013082531394","article-title":"Use of solid corrugated particles to enhance powder aerosol performance","volume":"18","author":"Chew","year":"2001","journal-title":"Pharm. Res. (N. Y.)"},{"key":"10.1016\/j.pupt.2018.03.005_bib20","doi-asserted-by":"crossref","first-page":"3259","DOI":"10.1002\/jps.24574","article-title":"Formulation of dry powders for inhalation","volume":"104","author":"Weers","year":"2015","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.pupt.2018.03.005_bib21","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1046\/j.1365-2125.2003.01892.x","article-title":"Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications","volume":"56","author":"Labiris","year":"2003","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.pupt.2018.03.005_bib22","unstructured":"U.S. Pharmacopeia Monograph Ciprofloxacin. http:\/\/www.pharmacopeia.cn\/v29240\/usp29nf24s0_m17865.html (Accessed 6 December 2017)."},{"key":"10.1016\/j.pupt.2018.03.005_bib23","unstructured":"European Pharmacopoeia Monograph Ciprofloxacin. http:\/\/online.edqm.eu\/EN\/entry.htm# (Accessed 6 December 2017)."},{"key":"10.1016\/j.pupt.2018.03.005_bib24","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1089\/jamp.2015.1282","article-title":"Ciprofloxacin dry powder for inhalation in patients with non-cystic fibrosis bronchiectasis or chronic obstructive pulmonary disease and in healthy volunteers","volume":"30","author":"Stass","year":"2017","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"key":"10.1016\/j.pupt.2018.03.005_bib25","doi-asserted-by":"crossref","first-page":"3974","DOI":"10.2174\/1381612821666150820105800","article-title":"The role of inspiratory pressures in determining flow rates through dry powder inhalers: a review","volume":"21","author":"Clark","year":"2015","journal-title":"Curr. Pharmaceut. Des."},{"key":"10.1016\/j.pupt.2018.03.005_bib26","doi-asserted-by":"crossref","first-page":"8","DOI":"10.2174\/1874306401408010008","article-title":"Inspiratory flows and volumes in subjects with non-CF bronchiectasis using a new dry powder inhaler device","volume":"8","author":"Elkins","year":"2014","journal-title":"Open Respir. Med. J."},{"key":"10.1016\/j.pupt.2018.03.005_bib27","first-page":"455","article-title":"Design of ciprofloxacin dry powder for inhalation","volume":"3","author":"Haynes","year":"2016","journal-title":"Reg. Dev. Dialog."},{"key":"10.1016\/j.pupt.2018.03.005_bib28","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.jaerosci.2003.09.002","article-title":"Predicting extrathoracic deposition from dry powder inhalers","volume":"35","author":"DeHaan","year":"2004","journal-title":"J. Aerosol Sci."},{"key":"10.1016\/j.pupt.2018.03.005_bib29","first-page":"185","article-title":"Choosing 3-D mouth-throat dimensions: a rational merging of medical imaging and aerodynamics","volume":"1","author":"Finlay","year":"2010","journal-title":"Respir. Drug Deliv."},{"key":"10.1016\/j.pupt.2018.03.005_bib30","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1089\/jamp.2012.0986","article-title":"Validation of a general in vitro approach for prediction of total lung deposition in healthy adults for pharmaceutical inhalation products","volume":"26","author":"Olsson","year":"2013","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"key":"10.1016\/j.pupt.2018.03.005_bib31","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1089\/jamp.2012.0975","article-title":"In vitro tests for aerosol deposition II: IVIVCs for different dry powder inhalers in normal adults","volume":"26","author":"Delvadia","year":"2013","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"key":"10.1016\/j.pupt.2018.03.005_bib32","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1089\/jamp.2014.1178","article-title":"In vitro\u2013in vivo correlations observed with indacaterol-based formulations delivered with the Breezhaler","volume":"28","author":"Weers","year":"2015","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"key":"10.1016\/j.pupt.2018.03.005_bib33","first-page":"325","article-title":"Dynamic inspiratory flow characteristics through the T-326 dry powder inhaler in cystic fibrosis","volume":"2","author":"Pavkov","year":"2013","journal-title":"RDD Eur."},{"key":"10.1016\/j.pupt.2018.03.005_bib34","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/j.clinthera.2013.08.003","article-title":"Tolerability and pharmacokinetic properties of ciprofloxacin dry powder for inhalation in patients with cystic fibrosis: a phase I, randomized, dose-escalation study","volume":"35","author":"Stass","year":"2013","journal-title":"Clin. Therapeut."},{"key":"10.1016\/j.pupt.2018.03.005_bib35","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1128\/AAC.30.4.614","article-title":"Pharmacokinetics and sputum penetration of ciprofloxacin in patients with cystic fibrosis","volume":"30","author":"Smith","year":"1986","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.pupt.2018.03.005_bib36","unstructured":"Cipro (ciprofloxacin hydrochloride) Tablets US Label. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/019537s073,020780s030lbl.pdf (Accessed 6 December 2017)."},{"key":"10.1016\/j.pupt.2018.03.005_bib37","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s40261-013-0082-0","article-title":"Inhalation of a dry powder ciprofloxacin formulation in healthy subjects: a phase I study","volume":"33","author":"Stass","year":"2013","journal-title":"Clin. Drug Invest."},{"key":"10.1016\/j.pupt.2018.03.005_bib38","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/j.1552-4604.1986.tb02938.x","article-title":"Single-dose pharmacokinetics of oral ciprofloxacin in patients with cystic fibrosis","volume":"26","author":"Goldfarb","year":"1986","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.pupt.2018.03.005_bib39","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1089\/jamp.2013.1056","article-title":"Safety and pharmacokinetics of ciprofloxacin dry powder for inhalation in cystic fibrosis: a phase I, randomized, single-dose, dose-escalation study","volume":"28","author":"Stass","year":"2015","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"key":"10.1016\/j.pupt.2018.03.005_bib40","doi-asserted-by":"crossref","first-page":"e000100","DOI":"10.1136\/bmjresp-2015-000100","article-title":"Ciprofloxacin DPI: a randomised, placebo-controlled, phase IIb efficacy and safety study on cystic fibrosis","volume":"2","author":"Dorkin","year":"2015","journal-title":"BMJ Open Respir. Res."},{"key":"10.1016\/j.pupt.2018.03.005_bib41","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1183\/09031936.00018414","article-title":"Inhaled antibiotics for stable non-cystic fibrosis bronchiectasis: a systematic review","volume":"44","author":"Brodt","year":"2014","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.pupt.2018.03.005_bib42","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1586\/ers.11.56","article-title":"Tobramycin Inhalation Powder\u2122: a novel drug delivery system for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis","volume":"5","author":"Parkins","year":"2011","journal-title":"Expet Rev. Respir. Med."},{"key":"10.1016\/j.pupt.2018.03.005_bib43","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jcf.2010.10.003","article-title":"Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: the EAGER trial","volume":"10","author":"Konstan","year":"2011","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.pupt.2018.03.005_bib44","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/1471-2466-14-107","article-title":"Treatment adherence and health outcomes in patients with bronchiectasis","volume":"14","author":"McCullough","year":"2014","journal-title":"BMC Pulm. Med."},{"key":"10.1016\/j.pupt.2018.03.005_bib45","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.addr.2014.08.013","article-title":"Antimicrobial therapy \u2013 barriers to effective treatment","volume":"85","author":"Weers","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.pupt.2018.03.005_bib46","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1186\/s12913-015-1004-z","article-title":"Defining the content and delivery of an intervention to Change AdhereNce to treatment in BonchiEctasis (CAN-BE): a qualitative approach incorporating the Theoretical Domains Framework, behavioral change techniques and stakeholder expert panels","volume":"15","author":"McCullough","year":"2015","journal-title":"BMC Health Serv. Res."},{"key":"10.1016\/j.pupt.2018.03.005_bib47","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1183\/13993003.01033-2015","article-title":"Changes in the incidence, prevalence and mortality of bronchiectasis in the UK from 2004 to 2013: a population-based cohort study","volume":"47","author":"Quint","year":"2016","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.pupt.2018.03.005_bib48","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1164\/rccm.201309-1575OC","article-title":"The Bronchiectasis Severity Index: an international derivation and validation study","volume":"189","author":"Chalmers","year":"2014","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.pupt.2018.03.005_bib49","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.rmed.2013.12.015","article-title":"Mortality in non-cystic fibrosis bronchiectasis: a prospective cohort analysis","volume":"108","author":"Goeminne","year":"2014","journal-title":"Respir. Med."},{"key":"10.1016\/j.pupt.2018.03.005_bib50","article-title":"Non cystic fibrosis bronchiectasis: a longitudinal retrospective observational cohort study of Pseudomonas persistence and resistance","author":"McDonnell","year":"2014","journal-title":"Respir. Med."},{"key":"10.1016\/j.pupt.2018.03.005_bib51","unstructured":"TOBI Podhaler Package Insert 2015. https:\/\/www.pharma.us.novartis.com\/sites\/www.pharma.us.novartis.com\/files\/tobipodhaler.pdf (Accessed 6 December 2017)."},{"key":"10.1016\/j.pupt.2018.03.005_bib52","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s41030-015-0007-6","article-title":"Colobreathe for the treatment of cystic fibrosis-associated pulmonary infections","volume":"1","author":"Schwarz","year":"2015","journal-title":"Pulm. Therapeut."},{"key":"10.1016\/j.pupt.2018.03.005_bib53","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jcf.2014.04.004","article-title":"Inhaled versus nebulised tobramycin: a real world comparison in adult cystic fibrosis (CF)","volume":"13","author":"Harrison","year":"2014","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.pupt.2018.03.005_bib54","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02052-2017","article-title":"RESPIRE 1: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis","volume":"51","author":"De Soyza","year":"2018","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.pupt.2018.03.005_bib55","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02053-2017","article-title":"RESPIRE 2: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis","volume":"51","author":"Aksamit","year":"2018","journal-title":"Eur. Respir. J."}],"container-title":["Pulmonary Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553918300063?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553918300063?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,22]],"date-time":"2018-08-22T15:20:41Z","timestamp":1534951241000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1094553918300063"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":55,"alternative-id":["S1094553918300063"],"URL":"https:\/\/doi.org\/10.1016\/j.pupt.2018.03.005","relation":{},"ISSN":["1094-5539"],"issn-type":[{"value":"1094-5539","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ciprofloxacin Dry Powder for Inhalation (ciprofloxacin DPI): Technical design and features of an efficient drug\u2013device combination","name":"articletitle","label":"Article Title"},{"value":"Pulmonary Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pupt.2018.03.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}